Amgen (AMGN) Non-Current Deferred Tax Liability (2013 - 2026)

Amgen has reported Non-Current Deferred Tax Liability for 13 years, with the latest figure at $1.3 billion in Q2 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 6.13% year-over-year to $1.3 billion in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 6.13% decrease from a year earlier, with the FY2025 full-year figure at $1.4 billion, down 59.08% from the prior year.
• Non-Current Deferred Tax Liability was $1.3 billion for Q2 2026 at Amgen, down from $1.3 billion in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $4.1 billion in Q4 2023, with the low at $1.3 billion in Q2 2026.
• Average Non-Current Deferred Tax Liability over 5 years is $1.9 billion, with a median of $1.6 billion recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Non-Current Deferred Tax Liability jumped 118.98% in 2023, then plunged 59.08% in 2025.
• Over 5 years, Non-Current Deferred Tax Liability stood at $1.9 billion in 2022, then surged by 118.98% to $4.1 billion in 2023, then dropped by 18.74% to $3.3 billion in 2024, then plunged by 59.08% to $1.4 billion in 2025, then retreated by 4.76% to $1.3 billion in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $1.3 billion (Q2 2026), $1.3 billion (Q1 2026), and $1.4 billion (Q4 2025), per Business Quant data.